FDA PMA FDA Class 2 Approved 🇺🇸 United States

Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers

PMA: P000021 · Supplement: S033 · Decision Apr 13, 2018
Classifications
1
FEI Numbers
37
Registration Numbers
37

Basic Information

Device Name
Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers
Trade Name
Dimension TPSA Flex Reagent Cartridge
PMA Number
P000021
Supplement Number
S033
Device Class
FDA Class 2
Product Code
LTJ
Generic Name
PROSTATE-SPECIFIC ANTIGEN (PSA) FOR MANAGEMENT OF PROSTATE CANCERS
Regulation Number
866.6010
Medical Specialty
Immunology
Advisory Committee
Immunology
Decision
Approved
Decision Code
APPR
Decision Date
April 13, 2018
Date Received
September 25, 2017
Supplement Type
Normal 180 Day Track No User Fee
Supplement Reason
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Expedited Review
N

Advisory Committee Statement

Approval of the instrument manufacturing site change for the Dimension® EXL integrated systems to the Siemens instrument manufacturing facility located in Flanders, New Jersey.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
LTJ Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers